Economic considerations in psoriasis management

Clinics in Dermatology

Volumn 26, Issue 5, 2008, Pages 424-431

  Radtke, Marc Alexander ^a   Augustin, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; STEROID; TAZAROTENE;

ARTICLE; BALNEOTHERAPY; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LABORATORY TEST; MEDICAL CARE; MONOTHERAPY; PHARMACOECONOMICS; PHOTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; ULTRAVIOLET B RADIATION;

DRUG COSTS; HEALTH CARE COSTS; HUMANS; PHOTOTHERAPY; PSORIASIS; QUALITY OF LIFE;

EID: 49849102152     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.10.024     Document Type: Article

References (95)

1. Augustin M., Zschocke I., Lange S., Seidenglanz K., and Amon U. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt 50 (1999) 715-722
2. Nijsten T., Meads D., de Korte J., Sampogna F., Gelfand J.M., Ongenae K., Evers A., and Augustin M. Cross cultural differences in responses to items of dermatology specific quality of life instruments among psoriasis patients. J Invest Dermatol 127 (2007) 2315-2322
3. Augustin M., and Zschocke I. Lebensqualität und Ökonomie bei allergischen Hauterkrankungen. Allergologie, Jahrgang 24 (2001) S. 433-S. 442
4. Rajagopalan R., and Anderson R. Impact of patch testing on dermatology-specific quality of life in patients with allergic contact dermatitis. Am J Contact Dermat 8 (1997) 215-221
5. Linnet J., and Jemec G.B. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br.J.Dermatol 140 (1999) 268-272
6. Poon E., Seed P.T., Greaves M.W., and Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 140 (1999) 667-671
7. Lundberg L., Johannesson M., Silverdahl M., Hermansson C., and Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm.Venereol 80 (2000) 430-434
8. Lundberg L., Johannesson M., Silverdahl M., Hermansson C., and Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br.J.Dermatol 141 (1999) 1067-1075
9. Zachariae R., Zachariae C., Ibsen H., Mortensen J.T., and Wulf H.C. Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm.Venereol 80 (2000) 272-276
10. O'Donnell B.F., Lawlor F.L., and Simpson Morgan J. The impact of chronic urticaria on the quality of life. Br J Dermatol 133 (1997) 27
11. Finlay A.Y., and Kahn G.K. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 9 (1994) 210-216
12. Chren M.M., Lasker R.J., Quinn L.M., Mostow E.N., and Zyzanski S.J. Skindex, a quality-of-life measure for patients with skin diseases: reliability, validity and responsiveness. J Invest Dermatol 107 (1996) 707-713
13. Zug K.A., Littenberg B., Baughman R.D., et al. Assessing the preferences of patients with psoriasis. Arch Dermatol 131 (1995) 561-568
14. Rapp S.R., Feldman S.R., Exum M.L., Fleisher Jr. A.B., and Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
15. Finzi A., Mantovani L., and Belisari A. Italian Association for Studies on Psoriasis. The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. J Eur Acad Dermatol Venereol 15 (2001) 320-324
16. Sohn S., Schoeffski O., Prinz J., et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212 (2006) 137-144
17. Berger K., Ehlken B., Kugland B., and Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 3 (2005) 511-518
18. Stern R.S., Nijsten T., Feldman S.R., Margolis D.J., and Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with wide-spread treatment dissatisfaction. J Investig Dermatol Symp Proc 9 (2004) 136-139
19. Rice T. Stichwort Gesundheitsökonomie. Eine kritische Auseinandersetzung (2004), KomPart-Verlag, Bonn
20. Drummond M.F., et al. Methods für the economic evaluation of health care Programmers. 3. überarb. Aufl (2005), Oxford University Press, Oxford
21. Beyer F., Zweifel P., and Kifmann M. Gesundheitsökonomik. 5. überarb (2005), Auflage Springer, Berlin, Heidelberg
22. Lauterbach K., and Schrappe M. Gesundheitsökonomie, Qualitätsmanagement und evidence-based medicine. Eine systematische Einführung. 2. überarb (2003), Auflage Schattauer, Stuttgart, New York
23. Oberender P., and Ecker T. Grundelemente der Gesundheitsökonomie (2001), PCO-Verlag Bayreuth
24. Lambert J.R.M.G. Cost-effectiveness of treatments in psoriasis. J Dermatol Treat 10 Suppl 1 (1999) 9-13
25. von der Schulenburg. Ökonomie in der Medizin (1996), Schattauer-Verlag, Stuttgart
26. Augustin M., Zschocke I., Wenninger K., et al. German adaption of the Skindex-29-Questionnair on quality of life in dermatology: validation and clinical results. Dermatology 209 (2004) 14-20
27. Galdari I., Rigel E., and Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol 15 (2001) 290-291
28. De Rie M., de Hoop D., Jönsson L., Bakkers E.J.M., and Sörensen M. Pharmacoeconomic evaluation of calcipotriol and UVB phototherapy in the treatment of psoriasis: a Markov model for the Netherlands. Dermatology 202 (2001) 38-43
29. Javitz H., Ward M., Farber E., Nail L., and Valoow S. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 46 (2002) 850-860
30. Crown W.H., Bresnahan B.W., Orsini L.S., Kennedy S., and Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Current Mediacl Research and Opinion 12 (2004) 1929-1936
31. Cockayne S.E., Cork M.J., and Gawkrodger D. Treatment of psoriasis: day care vs Inpatient therapy. Br J of Dermatol 140 (1999) 375
32. Koo J. Population based epidemiological study of psoriasis with emphasis on quality of life assessment. Pyschodermatol 14 (1996) 485-496
33. Kurwa H.A., and Finlay A.Y. Dermatology inpatient management greatly improves life quality. J Dermatol 133 (1995) 575-578
34. Finlay A.Y., and Coles E.C. The effects of severe psoriasis on the quality of life of patients. Br J Dermatol 132 (1995) 236-244
35. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994) 210-216
36. Rapp S.R., and Feldman S.R. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?. Dermatol Ther 17 (2004) 376-382
37. Gelfand J.M., Feldman S.R., TSren R.S., et al. Determinants of quality of life in patients with psoriasis: a study from US population. J Am Acad Dermatol 51 (2004) 704-708
38. Zachariae R., Zachariae C., Ibsen H.H., et al. Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. Acta Derm Venereol 84 (2004) 205-212
39. Ramsey B., and O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 8 (1988) 95-201
40. Fried R.G. Trivial or terrible? The psychological impact of psoriasis. Int J Dermatol 34 (1995) 101-105
41. Feldman S., Behnam S.M., Behnam S.E., and Koo J.Y. Involving the patient: impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol 53 1 Suppl 1 (2005) S78-S85
42. Fortune D.G., Richards H.L., Kirby B., et al. Psychological stress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 139 (2003) 752-756
43. Evers A.W., Lu Y., Duller P., van der Alk VP.G., Kraaimaat F.W., and van de Kerkhoff P.C. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol 152 (2005) 1275-1281
44. Kimball A.B., Acobson JC., Weiss S., Vreeland M.G., and Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 6 (2005) 383-392
45. Gupta M.A., and Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139 (1998) 846-850
46. Ginsberg I.C.H., and Link B.G. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 20 (1989) 53-63
47. Richards H.L., Fortune D.G., Griffiths C.E., and Main C.J. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 50 (2001) 11-15
48. Gupta M.A., and Gupta A.K. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 34 (1995) 700-703
49. Gupta M.A., and Gupta A.K. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 36 (1997) 259-262
50. Ryan T.J. Disability in dermatology. Br J Hosp Med 46 (1991) 33-36
51. Schmid-Ott G., Künsebeck H.W., Jäger B., et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derma Venereol 85 (2005) 27-32
52. Hornstein O.P., Brückner G.W., and Graf U. Über soziale Bewertung von Hautkrankheiten in der Bevölkerung-Methodik und Ergebnisse einer orientierenden Befragung. Hautarzt 24 (1973) 230-235
53. Schmid-Ott G. Stigmatisierung von Hauterkrankten. In: Petermann F., and Warschburger P. (Eds). Neurodermitis (1999), Hofgrefe, Göttingen S 157-S 174
54. Koblenzer C.S. The emotional impact of chronic and disabling skin disease: a psychoanalytic perspective. Dermatol Clin 23 (2005) 619-627
55. Unaeze J., Nijsten T., Murphy A., Ravichandran C., and Stern R. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol (2006) [adv. online publication]
56. Skevington S.M., Bradshaw A., Hepplewhite A., Dawkes K., and Lovell C.R. How does psoriasis affect quality of life? Assessing an Ingram-regimen outpatient programme and validating the WHOQOL-100. B J Dermaol 154 (2006) 680-691
57. Pearce D.J., Singh S., Balkrishnan R., Kulkarni A., Fleischer A.B., and Feldman S.R. The negative impact of psoriasis on the workplace. J Dermatolog Treat 17 (2006) 24-28
58. Sampogna F., Chren M.M., Melchi C.F., Pasquini P., Tabolli S., and Abeni D. Italian multipurpose psoriasis research on vital experiences (improve) study group. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 154 (2006) 325-331
59. Uttjek M., Dufaker M., Nygren L., and Stenberg B. Psoriasis care consumption and expectations from a gender perspective in a psoriasis population in northern Sweden. Acta Derm Venereol 85 (2005) 503-508
60. Fouere S., Adjadj L., and Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 19 Suppl 3 (2005) 2-6
61. Jankowiak B., Krajeswka-Kulak E., Baranowska A., Krajewska K., Rolka H., Sierakowska M., et al. The importance of the health education in life quality improvement in patients with psoriasis. Rocz Akad Med Bialymst 50 Suppl 1 (2005) 145-147
62. Katugampola R.P., Hongbo Y., and Finlay A.Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 152 (2005) 1256-1262
63. Young M. The psychological and social burden of psoriasis. Dermatol Nurs 17 (2005) 15-19
64. Feldman S.R., Clark A.R., Venkat A.P., FleischerJr A.B., Anderson R.T., and Rajagopalan R. The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol 152 (2005) 382-383
65. Grob J.J., Revuz J., Ortonne J.P., Auquier P., and Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. B J Dermatol 152 (2005) 289-295
66. Schmid-Ott G., Malewski P., Kreiselmaier I., and Mrowitz U. Psychological consequences of psoriasis-an empirical study of disease burden in 3753 affected people. Hautarzt 56 (2005) 466-472
67. De Korte J., Van Onselen J., Kownacki S., Sprangers M.A., and Bos J.D. Quality of care in patients with psoriasis: an clinical study of an international disease programme. J Eur Acad Dermatol Venereol 9 (2005) 35-41
68. O'Leary C.J., Creamer D., Higgins E., and Weinman J. Perceived stress, stress attributions and psychological distress in psoriasis. J Psychosom Res 57 (2004) 465-471
69. Gelfand J.M., Feldman S.R., Stern R.S., Thomas J., Rolstand T., and Margolis D.J. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 51 (2004) 704-708
70. Sampogna F., Sera F., and Abeni A. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 122 (2004) 602-607
71. Heydendael V.M., de Borgie C.A., Spuls P.I., Bossuyt P.M., Bos J.D., and de Rie M.A. The burden of psoriasis is not determined by disease severity only. J Invest Dermatol Symp Proc 9 (2004) 131-135
72. Uttjek M., Dufaker M., Nygren L., and Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol 84 (2004) 37-43
73. Schmidt-Ott G., Burchard R., Niederauer H.H., Lamprecht F., and Kunsebeck H.W. Stigmatization and quality of life of patients with psoriasis and atopic dermatitis. Hautarzt 54 (2003) 852-857 [Epub 2003 Jul 1]
74. Weiss S.C., Kimball A.B., Liewehr D.J., Blauvelt A., Turner M.L., and Emanuel E.J. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 47 (2002) 512-518
75. Akay A., Pekcanlar A., Bozdag K.E., Altintas L., and Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 16 (2002) 347-352
76. Zachariae R., Zachariae H., Blomqvist K., Davidsson S., Molin L., and Mork C. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 146 (2002) 1006-1016
77. Perrott S.B., Murray A.H., Lowe J., and Mathieson C.M. The psychological impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 70 (2000) 567-571
78. Lebwohl M., Siskin S.B., Epinette W., et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 35 (1996) 268-269
79. Lebwohl M., Yoles A., Lombardi K., and Lou W. Calcipotriene ointment and halobetasol ointment in the long-treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 39 (1998) 447-450
80. Lebwohl M.G., Breneman D.L., Goffe B.S., et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 39 (1998) 590-596
81. Bruce S., Epinette W.W., Funicella T., et al. Comparative study of calcipotriene (MC903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 31 (1994) 755-759
82. Weinstein G.D. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol 135 Suppl 49 (1996) 32-36
83. Peeters P., Ortonne J.P., Sitbon R., and Guignard E. Cost-effectiveness of once-daily treatment with calcipotriol/betamethason dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 211 (2005) 139-145
84. Krueger G., Koo J., Lebwohl M., Stern R., and Rolstad T. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137 (2001) 280-284
85. Marchetti A., LaPensee K., and An P. A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. Clin Ther 20 (1998) 851-869
86. Hartman M., Prins M., Swinkels O., Severens J., et al. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol 147 (2002) 538-544
87. Hankin C.S., et al. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends 17 (2005) 200-214
88. Schiffner R., Schiffner-Rohe J., Wölfl G., Landthaler M., Gläβl A., Walther T.H., Hofstädter F., and Stolz W. Evaluation of a multicentre study of synchronous application of narrowband ultraviolet B phototherapy (TL-01) and bathing in Dead Sea salt solution for psoriasis vulgaris. Br J Dermatol 142 (2000) 740-747
89. Sander H.M., Morris L.F., Phillips C.M., Harrison P.E., and Menter A. The annual cost of psoriasis. J Am Acad Dermatol 28 (1993) 422-425
90. Chen S., Shaheen A., and Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckermen therapy for psoriasis. Arch Dermatol 134 (1998) 1602-1608
91. Ellis C., Reiter K., Bandekar R., and Fendrick A. Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. J Am Acad Dermatol 46 (2002) 242-250
92. Pearce D.J., Nelson A.A., Fleischer A.B., Balkrishnan R., and Feldman S.R. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat 17 (2006) 29-37
93. Augustin M., Zschocke I., Seidenglanz K., Lange S., Schiffler A., and Amon U. Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom 1 (2000) 12-17
94. Augustin M., Amon U., Bullinger M., and Gieler U. Recommendations for the assessment of quality of life in dermatology. Dermatol Psychosom 1 (2000) 84-87
95. Augustin M., Radtke M., Moehling U., Peeters P., and Lapp C. Cost-effectiveness of psoriasis treatment with a combination of calcipotriol and betamethasone versus monosubstances-economic modeling by Markov method, in print. Dermatology (2007)